Based on the Fennec Pharmaceuticals Inc stock forecast from 2 analysts, the average analyst target price for Fennec Pharmaceuticals Inc is USD 13.00 over the next 12 months. Fennec Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Fennec Pharmaceuticals Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Fennec Pharmaceuticals Inc’s stock price was USD 5.65. Fennec Pharmaceuticals Inc’s stock price has changed by +10.78% over the past week, -15.29% over the past month and -38.85% over the last year.
No recent analyst target price found for Fennec Pharmaceuticals Inc
No recent average analyst rating found for Fennec Pharmaceuticals Inc
Company Overview Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Read Less
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sel...Read More
Frequently Asked Questions About Fennec Pharmaceuticals Inc (FENC) Stock
Based on ratings from 2 analysts Fennec Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on FENC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for FENC is USD 13.00 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 13.
FENC stock's Price/Earning ratio is 62.00.
Our analysis grades FENC stock's Price / Earning ratio at F. This means that FENC stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this FENC may be a overvalued for its sector.
The last closing price of FENC's stock was USD 5.65.
The most recent market capitalization for FENC is USD 0.14B.
Based on targets from 2 analysts, the average taret price for FENC is projected at USD 13.00 over the next 12 months.
This means that FENC's stock price may go up by +130.09% over the next 12 months.
We can't find any ETFs which contains Fennec Pharmaceuticals Inc's stock.
As per our most recent records Fennec Pharmaceuticals Inc has 32 Employees.
Fennec Pharmaceuticals Inc's registered address is 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709.
You can get more information about it from Fennec Pharmaceuticals Inc's website at https://www.fennecpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Fennec Pharmaceuticals Inc (FENC) Stock
Based on ratings from 2 analysts Fennec Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on FENC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for FENC is USD 13.00 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 13.
FENC stock's Price/Earning ratio is 62.00.
Our analysis grades FENC stock's Price / Earning ratio at F. This means that FENC stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this FENC may be a overvalued for its sector.
The last closing price of FENC's stock was USD 5.65.
The most recent market capitalization for FENC is USD 0.14B.
Based on targets from 2 analysts, the average taret price for FENC is projected at USD 13.00 over the next 12 months.
This means that FENC's stock price may go up by +130.09% over the next 12 months.
We can't find any ETFs which contains Fennec Pharmaceuticals Inc's stock.
As per our most recent records Fennec Pharmaceuticals Inc has 32 Employees.
Fennec Pharmaceuticals Inc's registered address is 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709.
You can get more information about it from Fennec Pharmaceuticals Inc's website at https://www.fennecpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FENC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
